Orencia (abatacept)

These findings provide preclinical proof-of-concept that BLINA and ABATA can be combined to uncouple GvL from GvHD. This strategy preserves CD28-independent T-cell cytotoxicity while limiting allo-reactivity, providing a strong rationale for investigating this combination in the post-transplant setting.

P1/2, N=29, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | Trial completion date: Dec 2023 --> Jan 2026

A 77-year-old woman with stage IV serous endometrial carcinoma presented 24 days after a single dose of carboplatin, paclitaxel, and pembrolizumab, with progressive weakness, ptosis, diplopia, and respiratory compromise...She was treated with pulse corticosteroids and plasma exchange (PLEX), with rituximab added after the second session for an inadequate response. Persistent myocarditis with sustained troponin elevation prompted further escalation to abatacept and ruxolitinib...The case is distinguished by refractory disease requiring four sequential lines of immunosuppression, concurrent immune-mediated hepatitis and thyroiditis, and a seronegative myasthenia gravis profile, consistent with the more heterogeneous, non-antibody-mediated mechanisms increasingly recognized in ICI-induced disease. It informs treatment escalation in refractory cases and underscores three principles essential to managing this high-mortality syndrome: early recognition, systematic screening for all syndromic components once any one is identified, and timely escalation through multiple lines of immunosuppression when disease proves refractory.

P3, N=34, Completed, University Hospital, Brest | Active, not recruiting --> Completed

P3, N=400, Recruiting, Duke University | Trial primary completion date: Jun 2026 --> Dec 2026

P2, N=45, Not yet recruiting, St. Jude Children's Research Hospital

P1/2, N=74, Recruiting, Northwell Health | Active, not recruiting --> Recruiting | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Dec 2025 --> Aug 2026

P1/2, N=56, Completed, Beth Israel Deaconess Medical Center | Phase classification: P1 --> P1/2

Rather than a static inhibitory receptor, CTLA-4 is better viewed as a context-dependent regulatory pathway whose function depends on trafficking, surface availability, and cellular context. This perspective links molecular mechanism to clinical phenotype and supports more precise CTLA-4-targeted therapy.

Among RA patients, older age, male sex, smoking, abatacept use, and comorbidities may be associated with increased tumor risk, while TNFi use may be associated with lower risk. Clinicians should consider these factors to identify high-risk populations for enhanced monitoring.

P1/2, N=90, Recruiting, National Heart, Lung, and Blood Institute (NHLBI)

This comprehensive pharmacovigilance study mapped drug-MC associations, suggesting potential novel safety signals while corroborating previously reported agents. Immunomodulatory drugs emerged as substantial risk factors. These findings provide practical insights for clinicians managing patients with MC.